CARLSBAD, Calif., June 16, 2015 /PRNewswire/ -- Isis
Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense
therapeutics, today announced that management will present a
general corporate update in conjunction with its 2015 Annual
Meeting of Stockholders and Open House on Tuesday, June 30 at 2:10
p.m. Pacific Time in Carlsbad,
CA.
The agenda for the meeting is as follows:
2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only
for stockholders of record as of May 4,
2015)
2:10 p.m. – 3:00 p.m. Corporate Presentation – Stanley T. Crooke, Isis' Chairman and Chief
Executive Officer
3:00 p.m. – 5:00 p.m. Scientific Poster Presentation and Open
House
A live audio webcast of the presentation will be available on
the "Investors & Media" section of the Company's Web site,
www.isispharm.com. A replay of the presentation will be
available on the Isis Web site within 48 hours and will be archived
for a limited time.
To RSVP to attend the meeting, please go to Isis' Home Page at
www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in RNA-targeted
technology to discover and develop novel drugs for its product
pipeline and for its partners. Isis' broad pipeline consists
of 38 drugs to treat a wide variety of diseases with an emphasis on
cardiovascular, metabolic, severe and rare diseases, including
neurological disorders, and cancer. Isis' partner, Genzyme,
is commercializing Isis' lead product, KYNAMRO®, in
the United States and other
countries for the treatment of patients with homozygous FH.
Isis has numerous drugs in Phase 3 development in severe/rare
diseases and cardiovascular diseases. These include
ISIS-APOCIIIRx, a drug Isis is developing and plans to
commercialize through its wholly owned subsidiary, Akcea
Therapeutics, to treat patients with familial chylomicronemia
syndrome and familial partial lipodystrophy; ISIS-TTRRx,
a drug Isis is developing with GSK to treat patients with the
polyneuropathy and cardiomyopathy forms of TTR amyloidosis; and
ISIS-SMNRx, a drug Isis is developing with Biogen to
treat infants and children with spinal muscular atrophy, a severe
and rare neuromuscular disease. Isis' patents provide strong
and extensive protection for its drugs and technology.
Additional information about Isis is available at
www.isispharm.com.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements regarding
Isis Pharmaceuticals' financial position and outlook, Isis'
business, and the therapeutic and commercial potential of Isis'
technologies and products, including KYNAMRO,
ISIS-APOCIIIRx, ISIS-SMNRx and
ISIS-TTRRx, in development. Any statement
describing Isis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such
statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering,
developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a
business around such drugs. Isis' forward-looking statements
also involve assumptions that, if they never materialize or prove
correct, could cause its results to differ materially from those
expressed or implied by such forward-looking statements.
Although Isis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Isis. As a result, you
are cautioned not to rely on these forward-looking
statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31,
2014, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other
documents are available from the Company.
In this press release, unless the context requires otherwise,
"Isis," "Company," "we," "our," and "us" refers to Isis
Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals® is a registered trademark of
Isis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark
of Isis Pharmaceuticals, Inc. KYNAMRO® is a
registered trademark of Genzyme Corporation.
Logo -
http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isis-pharmaceuticals-to-present-a-general-corporate-update-at-its-2015-annual-meeting-of-stockholders-and-open-house-300099413.html
SOURCE Isis Pharmaceuticals, Inc.